What does PD-1/PD-L1 immunotherapy involve?
This treatment uses Chinese-manufactured checkpoint inhibitors, such as Tislelizumab or Sintilimab, which are administered intravenously over approximately 30 minutes every three weeks. These drugs block the PD-1/PD-L1 pathway, reactivating your immune system's T-cells to recognize and attack cancer cells. It is an outpatient procedure, so you can return home shortly after each infusion.
Perguntas relacionadas
Ainda tem dúvidas?
Nossa equipe está aqui para ajudar. Envie sua pergunta — respondemos em 24 horas.
Fazer uma Pergunta